Karin Jannet Vera López

Dr. Karin Jannet Vera López

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2007 in Journal of Chromatography B
Verified
Journal Article
Closed access
KLKarin Jannet Vera López
Karin Jannet Vera López
DBD. Faria Bertoluci
D. Faria Bertoluci
KVK.M. Vicente
K.M. Vicente
ADA.M. Dell’aQuilla
A.M. Dell’aQuilla
SSS.R.C. Jorge Santos
S.R.C. Jorge Santos

29 December 2020 in Journal of Alzheimer's Disease Reports
Verified
Journal Article
Open access
PDF file
MCMiguel A. Chávez-Fumagalli
Miguel A. Chávez-Fumagalli
PSPallavi Shrivastava
Pallavi Shrivastava
JAJorge A. Aguilar-Pineda
Jorge A. Aguilar-Pineda
RNRita Nieto-Montesinos
Rita Nieto-Montesinos
GDGonzalo Davila Del-Carpio
Gonzalo Davila Del-Carpio
CCchristian lino cardenas
christian lino cardenas
Background: The present systematic review and meta-analysis of diagnostic test accuracy summarizes the last three decades in advances on diagnosis of Alzheimer’s disease (AD) in developed and developing countries. Objective: To determine the accuracy of biomarkers in diagnostic tools in AD, for example, cerebrospinal fluid, positron emission tomography (PET), and magnetic resonance imaging (MRI), etc. Methods: The authors searched PubMed for published studies from 1990 to April 2020 on AD diagnostic biomarkers. 84 published studies were pooled and analyzed in this meta-analysis and diagnostic accuracy was compared by summary receiver operating characteristic statistics. Results: Overall, 84 studies met the criteria and were included in a meta-analysis. For EEG, the sensitivity ranged from 67 to 98%, with a median of 80%, 95% CI [75, 91], tau-PET diagnosis sensitivity ranged from 76 to 97%, with a median of 94%, 95% CI [76, 97]; and MRI sensitivity ranged from 41 to 99%, with a median of 84%, 95% CI [81, 87]. Our results showed that tau-PET diagnosis had higher performance as compared to other diagnostic methods in this meta-analysis. Conclusion: Our findings showed an important discrepancy in diagnostic data for AD between developed and developing countries, which can impact global prevalence estimation and management of AD. Also, our analysis found a better performance for the tau-PET diagnostic over other methods to diagnose AD patients, but the expense of tau-PET scan seems to be the limiting factor in the diagnosis of AD in developing countries such as those found in Asia, Africa, and Latin America.

Verified
Journal Article
Open access
PDF file
JAJorge Alberto Aguilar-Pineda
Jorge Alberto Aguilar-Pineda
MAMazen Albaghdadi
Mazen Albaghdadi
WJWanlin Jiang
Wanlin Jiang
KLKarin Jannet Vera López
Karin Jannet Vera López
RNRita Milagros Nieto-Montesinos
Rita Milagros Nieto-Montesinos
CCchristian lino cardenas
christian lino cardenas
Emerging evidence suggests that males are more susceptible to severe infection by the SARS-CoV-2 virus than females. A variety of mechanisms may underlie the observed gender-related disparities including differences in sex hormones. However, the precise mechanisms by which female sex hormones may provide protection against SARS-CoV-2 infectivity remains unknown. Here we report new insights into the molecular basis of the interactions between the SARS-CoV-2 spike (S) protein and the human ACE2 receptor. We further report that glycosylation of the ACE2 receptor enhances SARS-CoV-2 infectivity. Importantly, estrogens can disrupt glycan–glycan interactions and glycan–protein interactions between the human ACE2 and the SARS-CoV-2 thereby blocking its entry into cells. In a mouse model of COVID-19, estrogens reduced ACE2 glycosylation and thereby alveolar uptake of the SARS-CoV-2 spike protein. These results shed light on a putative mechanism whereby female sex hormones may provide protection from developing severe infection and could inform the development of future therapies against COVID-19.

28 January 2022 in Molecules
Verified
Journal Article
Open access
PDF file
Luis Daniel Goyzueta-MamaniLuis Daniel Goyzueta-Mamani
Luis Daniel Goyzueta-Mamani
Haruna L. Barazorda-CcahuanaHaruna L. Barazorda-Ccahuana
Haruna L. Barazorda-Ccahuana
Miguel Angel Chavez FumagalliMiguel Angel Chavez Fumagalli
Miguel Angel Chavez Fumagalli
KAKarla L. F. Alvarez
Karla L. F. Alvarez
JAJorge Alberto Aguilar-Pineda
Jorge Alberto Aguilar-Pineda
CCchristian lino cardenas
christian lino cardenas
Background: Despite research on the molecular bases of Alzheimer’s disease (AD), effective therapies against its progression are still needed. Recent studies have shown direct links between AD progression and neurovascular dysfunction, highlighting it as a potential target for new therapeutics development. In this work, we screened and evaluated the inhibitory effect of natural compounds from native Peruvian plants against tau protein, amyloid beta, and angiotensin II type 1 receptor (AT1R) pathologic AD markers. Methods: We applied in silico analysis, such as virtual screening, molecular docking, molecular dynamics simulation (MD), and MM/GBSA estimation, to identify metabolites from Peruvian plants with inhibitory properties, and compared them to nicotinamide, telmisartan, and grapeseed extract drugs in clinical trials. Results: Our results demonstrated the increased bioactivity of three plants’ metabolites against tau protein, amyloid beta, and AT1R. The MD simulations indicated the stability of the AT1R:floribundic acid, amyloid beta:rutin, and tau:brassicasterol systems. A polypharmaceutical potential was observed for rutin due to its high affinity to AT1R, amyloid beta, and tau. The metabolite floribundic acid showed bioactivity against the AT1R and tau, and the metabolite brassicasterol showed bioactivity against the amyloid beta and tau. Conclusions: This study has identified molecules from native Peruvian plants that have the potential to bind three pathologic markers of AD.

1 June 2008 in Clinics
Verified
Journal Article
Open access
PDF file
VSVeronica Santos
Veronica Santos
KLKarin Jannet Vera López
Karin Jannet Vera López
LSLuciana Moraes Santos
Luciana Moraes Santos
MYMauricio Yonamine
Mauricio Yonamine
Maria CarmonaMaria Carmona
Maria Carmona
SSSilvia Regina Cavani Jorge Santos
Silvia Regina Cavani Jorge Santos
To implement a selective and sensitive analytical method to quantify morphine in small volumes of plasma by gas-liquid chromatography-mass spectrometry (GC-MS), aimed at post-operatively monitoring the drug. A gas-liquid chromatographic method with mass detection has been developed to determine morphine concentration in plasma after solid phase extraction. Morphine-d3 was used as an internal standard. Only 0.5 mL of plasma is required for the drug solid-phase extraction in the Bond Elut-Certify, followed by the quantification of morphine derivative by GC-MS using a linear temperature program, a capillary fused silica column, and helium as the carrier and make-up gas. The method was applied to determine morphine content in plasma samples of four patients during the postoperative period of cardiac surgery. Patient-controlled analgesia with morphine was performed by a venous catheter, and a series of venous blood samples were collected. After the oro-After the orotracheal extubation, morphine plasma levels were monitored for up to 36 hours. The run time was 16 minutes because morphine and the internal standard were eluted after 8.8 minutes. The GC-MS method had 0.5 -1000 ng/mL linearity range (r(2)=0.9995), 0.1 ng/mL limit of detection, intraday and interday precision equivalent to 1.9% and 6.8%, and 0.1% and 0.8% systematic error (intraday and interday, respectively). The analytical method showed optimal absolute (98%) and relative (100.7%) recoveries. Morphine dose requirements and plasma levels are discussed. The analytical gas-liquid chromatography-mass spectrometry method is selective and adequate for morphine measurements in plasma for applications in clinical studies.

25 March 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
JAJorge Alberto Aguilar-Pineda
Jorge Alberto Aguilar-Pineda
SPSilvana G. Paco-Coralla
Silvana G. Paco-Coralla
CFCamilo Febres-Molina
Camilo Febres-Molina
PGPamela L. Gamero-Begazo
Pamela L. Gamero-Begazo
PSPallavi Shrivastava
Pallavi Shrivastava
CCchristian lino cardenas
christian lino cardenas
Apolipoprotein E4 (ApoE4) is thought to increase the risk of developing Alzheimer’s disease. Several studies have shown that ApoE4-Amyloid β (Aβ) interactions can increment amyloid depositions in the brain and that this can be augmented at low pH values. On the other hand, experimental studies in transgenic mouse models have shown that treatment with enoxaparin significantly reduces cortical Aβ levels, as well as decreases the number of activated astrocytes around Aβ plaques. However, the interactions between enoxaparin and the ApoE4-Aβ proteins have been poorly explored. In this work, we combine molecular dynamics simulations, molecular docking, and binding free energy calculations to elucidate the molecular properties of the ApoE4-Aβ interactions and the competitive binding affinity of the enoxaparin on the ApoE4 binding sites. In addition, we investigated the effect of the environmental pH levels on those interactions. Our results showed that under different pH conditions, the closed form of the ApoE4 protein, in which the C-terminal domain folds into the protein, remains stabilized by a network of hydrogen bonds. This closed conformation allowed the generation of six different ApoE4-Aβ interaction sites, which were energetically favorable. Systems at pH5 and 6 showed the highest energetic affinity. The enoxaparin molecule was found to have a strong energetic affinity for ApoE4-interacting sites and thus can neutralize or disrupt ApoE4-Aβ complex formation.